Test Price
2,800 AED✅ Home Collection Available
CREB3L1 Genetic Test for Osteogenesis Disorders | 2800 AED | 2026 DHA Guidelines
تحليل تسلسل جين CREB3L1 في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139).
Premium Logistics: Paid Hospital‑Grade Home Collection via ISO Certified Cold‑Chain (Whole Blood / FTA Card).
Clinical Guidance: Telephonic Post‑Test Clinical Guidance for result interpretation by DHA‑licensed clinical team.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
ملخص تنفيذي: دقة تشخيصية تفوق 99.9% باستخدام تقنيات تسلسل الجيل التالي (NGS) تحت رقابة جودة ISO 9001:2015. خدمة سحب الدم المتميزة من منزلك مع سلسلة تبريد دقيقة، وإرشاد سريري هاتفي بعد النتيجة، وتدقيق تأميني فوري للإجراءات داخل دولة الإمارات.
At‑a‑Glance: What You Need to Know
The CREB3L1 next‑generation sequencing (NGS) panel analyzes the entire coding region of the CREB3L1 gene, which is critical in osteogenesis imperfecta type III and related connective tissue pathologies. This test provides molecular confirmation for suspected osteology‑dermatology‑immunology disorders, guiding surveillance and family planning decisions with a turnaround of 3–4 weeks.
يكشف تحليل الجين CREB3L1 بتقنية التسلسل المتقدم عن الطفرات المسببة لتكوُّن العظم الناقص والأمراض الجلدية المناعية، مما يسهم في وضع خطة علاجية دقيقة تتوافق مع إرشادات هيئة الصحة بدبي.
| Feature | Our CREB3L1 NGS Test | Closest Standard Alternative |
|---|---|---|
| Precision | Full‑gene sequencing with copy number analysis (99.9% analytic sensitivity) | Limited hotspot genotyping (~80% mutation coverage) |
| Methodology | Next‑Generation Sequencing (NGS) on Illumina® platform, CNV calling | Sanger sequencing of selected exons |
| Turnaround & Logistics | 21–28 days, hospital‑grade home collection 8 AM – 11 PM, cold‑chain transport | 28–42 days, clinic visit required, ambient shipping |
Physician Insight & Safety Protocol
“As a DHA‑licensed physician, I emphasize that a positive CREB3L1 variant must always be correlated with clinical and radiologic findings before making management decisions. This NGS result is a precision tool that, when combined with a detailed phenotypic assessment, enables early intervention in osteogenesis imperfecta and related connective tissue disorders. I strongly encourage patients to discuss cascade testing with a clinical geneticist after receiving this report.”
— Dr. PRABHAKAR REDDY, DHA License No. 61713011
⚠ Important Medication Notice
Do not discontinue any prescribed medication or supplement without consulting your treating physician. Genetic testing does not replace ongoing clinical management; your current therapy should remain unchanged until your doctor reviews the final genetic report.
🛑 Safety Exclusion Criteria & When to Seek Emergency Care
- Exclusion from home collection: Individuals unable to provide valid, legally authorized informed consent (including minors without a guardian per UAE CDS Law 2026), or those with active cutaneous infection over all venipuncture sites.
- Sample rejection risk: Extreme lipaemia, haemolysis, or insufficient volume may require recollection; our phlebotomist will assess vein quality on arrival.
- Emergency red flags (seek immediate medical attention): Sudden unexplained fracture with neurovascular compromise, acute respiratory distress, or signs of malignant jaundice – these conditions are unrelated to the collection but require urgent hospital evaluation.
Frequently Asked Questions
1. What is the clinical utility of the CREB3L1 NGS test, and who should consider it?
Snippet: The CREB3L1 NGS test confirms osteogenesis imperfecta spectrum disorders by detecting pathogenic variants in the entire coding region, aiding definitive diagnosis in patients with recurrent fractures or dentinogenesis imperfecta. It is indicated for individuals with clinical signs of brittle bone disease, hyperextensible joints, early‑onset hearing loss, or family history of OI; also valuable for prenatal diagnosis when a familial mutation is known. A consultation with a clinical geneticist or orthopedic specialist is required before ordering.
ما الفائدة السريرية لتحليل CREB3L1 الجيني ومن يجب أن يجريه؟
يؤكد هذا التحليل الجيني طيف تكوّن العظم الناقص عبر كشف الطفرات في كامل المنطقة المشفّرة، ويُوجَّه للأشخاص ذوي الكسور المتكررة أو تشوهات الأسنان والعظام. يُوصى به بعد استشارة طبيب الوراثة أو جراح العظام.
2. How should I prepare for the sample collection, and why is a genetic counselling session needed before the test?
Snippet: Preparation is minimal; however, a pre‑test genetic counselling session is mandatory to draw a detailed family pedigree and ensure appropriate test selection for the CREB3L1 gene. No fasting is required; simply provide whole blood or an FTA card spot. The counselling session, available telephonically or in‑clinic, reviews inheritance patterns, variant interpretation possibilities, and implications for at‑risk relatives, aligning with UAE PDPL privacy standards.
كيف أستعد لجمع العينة وما أهمية جلسة الاستشارة الوراثية قبل الفحص؟
لا تحتاج إلى صيام، لكن جلسة الاستشارة الوراثية المسبقة إلزامية لرسم شجرة العائلة بدقة، ويستطيع أخصائي الوراثة تقديمها هاتفياً لضمان الفهم الصحيح للنتائج المحتملة. تُسحب العينة بالطريقة المنزلية المريحة.
3. How quickly will I receive my results, and what support is provided after the report is issued?
Snippet: You will receive your CREB3L1 genetic report within 21–28 days, fully compliant with ISO 9001:2015 and DHA reporting standards, including variant classification and clinical correlation guidance. Post‑ telephonic guidance with our clinical team is included; you may also request a referral to a DHA‑licensed genetic counsellor. The report can be shared securely with your treating physician for integration into your care plan.
متى سأستلم تقريري وما هو الدعم المتاح بعد صدوره؟
تصدر النتيجة خلال 21 إلى 28 يوماً، مع جلسة إرشاد هاتفية مجانية لتفسير التقرير. يمكن تحويلك إلى استشاري وراثة معتمد من هيئة الصحة بدبي لمتابعة الخطة العلاجية.
UAE Regulatory Compliance & Accreditation
This medical laboratory service complies with Federal Decree‑Law No. 41 of 2024 (Art. 87), the UAE Children’s Digital Safety Law 2026 for minor consent protocols, and the UAE Personal Data Protection Law (PDPL). Facility License: 9834453. ISO 9001:2015 Quality Management System certified (Certificate No. INT/EGQ/2509DA/3139). All genetic counselling sessions are performed by DHA‑licensed professionals.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians